HOUSTON, Texas, January 4, 2021 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a treatment against the inflammatory response and associated complications brought on by COVID-19.
HOUSTON, Texas, October 8, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures (MCMs).
As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist
HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO will provide project management, contract management, and clinical trial site support to participating military treatment facility investigative sites. Pharm-Olam will be partnering with The Geneva Foundation (Geneva), which is dedicated to serving military medical researchers with the on-site support needed to operationalize clinical trials.
Houston, June 24, 2020 – Pharm-Olam, a global midsized clinical research organization (CRO), today announced that they completed a change of ownership transaction on Friday June 19, 2020. This transaction provides Pharm-Olam with enhanced financial flexibility and access to additional capital to support its growth strategy, as it continues to enhance their services in the company’s five core therapeutic areas: oncology-hematology, infectious disease and vaccines, autoimmune, allergy and rare disease.
Houston, June 16th, 2020 – Pharm-Olam, LLC, a global, midsized CRO offering full-service clinical development solutions to the pharmaceutical and biotech industry, is launching Protocol Optimization Services to support the study development needs of their biopharma clients. The Protocol Optimization Service will benchmark a sponsor’s study design against other similar clinical trials and identify optimization opportunities for consideration and inclusion. This service will aid the development of lean and cost-effective study design while also maximizing study value through balancing patient and site burden with the achievement of planned primary and secondary study endpoints.
HOUSTON, TX, April 29, 2020– Pharm-Olam, a leading mid-sized clinical research organization (CRO) serving the pharmaceutical and biotech industry, won multiple recognitions in Life Science Leader magazine’s 2020 CRO Leadership Awards. This year marks the second consecutive year in which Pharm-Olam won CRO Leadership Awards. In 2019, the clinical research organization received awards in Compatibility, Reliability, and Quality. Building on that operational success, Pharm-Olam received awards in five of the six categories recognized by Life Science Leader. Pharm-Olam won a 2020 CRO Leadership Award in the following categories:
Collaboration between Pharm-Olam and IAOCR ensures “quality built in” audits Houston, Texas and Maidenhead, United Kingdom, 27 April 2020 – The first Independently Accredited Clinical Research Audit Academy is registering delegates for its first cohort commencing 4 May. “Audit Academy” blends high-quality virtual training and development facilitated by Pharm-Olam, with robust, independent and internationally-recognized accreditation awarded by IAOCR to deliver Internationally Qualified Clinical Research Auditors (designatory letters AIACR1).
TORONTO, March 25, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases completing over 100 clinical studies in approximately 19,000 patients at over 2,000 clinical sites, to serve as the Company’s Contract Research Organization (“CRO”) to advance the future clinical study for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (“COVID-19”). In addition, Revive has added Dr. Kelly McKee, Jr., MD, MPH as Chief Scientific Officer consultant and Dr. Onesmo Mpanju, PhD as Regulatory Affairs consultant to the Company’s clinical development team.